144 related articles for article (PubMed ID: 7781147)
1. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
3. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
[TBL] [Abstract][Full Text] [Related]
4. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
5. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC
Eur J Cancer; 1992; 28(2-3):415-20. PubMed ID: 1591054
[TBL] [Abstract][Full Text] [Related]
6. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
[TBL] [Abstract][Full Text] [Related]
7. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
8. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
9. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
[TBL] [Abstract][Full Text] [Related]
10. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
11. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
Geisler J; Johannessen DC; Anker G; Lønning PE
Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
[TBL] [Abstract][Full Text] [Related]
12. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
13. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.
Cunningham D; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Ford HT; Gazet JC; Coombes RC
Cancer Chemother Pharmacol; 1987; 20(3):253-5. PubMed ID: 3677299
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
[TBL] [Abstract][Full Text] [Related]
15. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
[TBL] [Abstract][Full Text] [Related]
16. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
17. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC
Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384
[TBL] [Abstract][Full Text] [Related]
18. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Di Leo A; Bartoli C; Merson M; Sacchini V; Moglia D; Celio L
Br J Cancer; 1994 Jul; 70(1):145-50. PubMed ID: 8018527
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
[TBL] [Abstract][Full Text] [Related]
20. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Dowsett M; Coombes RC
Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]